Stocktoria
IN8BIO, INC. INAB
IN8BIO, INC. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $10.2M | $17.0M | $16.8M | $14.1M | $7.3M | $5.4M |
| Operating income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M | -$8.6M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M | -$8.6M |
| EPS (diluted) | $-4.44 | $-17.05 | $-1.00 | $-1.36 | $-1.47 | — |
| Operating cash flow | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M | -$7.1M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M | $20.9M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M | $2.6M |
| Shareholders' equity | $27.6M | $14.5M | $24.9M | $22.7M | -$38.2M | -$16.6M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.